Kepler Capital Markets Reaffirms Buy Rating for AstraZeneca plc (AZN)

AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reissued by stock analysts at Kepler Capital Markets in a report issued on Thursday, July 13th. They presently have a GBX 5,500 ($72.55) price target on the biopharmaceutical company’s stock. Kepler Capital Markets’ target price would indicate a potential upside of 20.56% from the company’s current price.

Several other research analysts have also commented on the stock. Citigroup Inc. reaffirmed a “buy” rating and issued a GBX 6,000 ($79.15) price target on shares of AstraZeneca plc in a report on Thursday, July 13th. Deutsche Bank AG dropped their price objective on shares of AstraZeneca plc from GBX 5,500 ($72.55) to GBX 5,350 ($70.57) and set a “buy” rating on the stock in a research note on Friday, April 28th. Barclays PLC reissued an “overweight” rating and issued a GBX 6,000 ($79.15) target price on shares of AstraZeneca plc in a research report on Monday, March 27th. HSBC Holdings plc downgraded shares of AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($59.36) target price for the company. in a research report on Tuesday, July 4th. Finally, Societe Generale reaffirmed a “buy” rating on shares of AstraZeneca plc in a report on Thursday, March 23rd. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 4,956.48 ($65.38).

Shares of AstraZeneca plc (LON:AZN) traded up 1.38% during mid-day trading on Thursday, reaching GBX 4562.00. The company’s stock had a trading volume of 2,013,875 shares. The stock has a 50 day moving average of GBX 5,101.58 and a 200-day moving average of GBX 4,861.19. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The stock’s market cap is GBX 57.74 billion.

WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/03/astrazeneca-plc-azn-stock-rating-reaffirmed-by-kepler-capital-markets-updated-updated.html.

In related news, insider Nazneen Rahman bought 39 shares of the company’s stock in a transaction on Thursday, July 27th. The shares were purchased at an average cost of GBX 4,370 ($57.64) per share, for a total transaction of £1,704.30 ($2,248.12).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

6 + 8 =